Johnson & Johnson Family of Companies
1 Johnson & Johnson Plaza
New Brunswick
New Jersey
08933
United States
Tel: 732-524-0400
Fax: 732-524-3300
Website: http://www.jnj.com/
2571 articles with Johnson & Johnson Family of Companies
-
Janssen’s Tremfya, an IL-23 inhibitor, is showing an ability to separate itself from AbbVie’s Skyrizi in preventing the activation of cells that drive inflammation.
-
Johnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
5/12/2022
Johnson & Johnson will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort, Rancho Palos Verdes, CA on Thursday, June 16th.
-
An investigation conducted by the U.S. House of Representatives shows Emergent was forced to destroy nearly 400 million doses of the vaccine. The company disputes the report’s claim.
-
Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company
5/11/2022
Johnson & Johnson announced the appointment of Thibaut Mongon as Chief Executive Officer Designate and Paul Ruh as Chief Financial Officer Designate of the future, listed New Consumer Health Company.
-
Three long-time FDA officials, Dr. Peter Marks, Dr. Janet Woodcock and Dr. Robert Califf wrote an op-ed in JAMA describing the reality that COVID-19 represents “the new normal.”
-
Teva announced that it had reached a deal with Lupin over Lupin’s Abbreviated New Drug Application (ANDA) for generic deutetrabenazine - an upcoming competitor to Hungtington's drug Austedo.
-
Emergent BioSolutions Founder and former chief executive officer Fuad El-Hibri has died, the company reported.
-
Johnson & Johnson to Participate in the Bernstein 38th Annual Strategic Decisions Conference
5/2/2022
Johnson & Johnson will participate in the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1st, at the New York Hilton Midtown in New York.
-
Zymeworks received an unsolicited, non-binding acquisition offer from global investment firm All Blue Capital. All Blue is offering $10.50 per share for a total of $773 million in cash.
-
Gilead’s Veklury made massive profits, but as more vaccine boosters arrive and more people become immune to the virus, the future of the antiviral is in question.
-
Weeks after Gilead Sciences raised concern over counterfeit HIV drugs, Johnson & Johnson has taken similar action against the distribution of counterfeit prescription drugs.
-
Johnson & Johnson to Participate in the UBS Global Healthcare Conference
4/20/2022
Johnson & Johnson will participate in the UBS Global Healthcare Conference on Tuesday, May 24th.
-
Johnson & Johnson Reports Q1 2022 Results
4/19/2022
Johnson & Johnson announced results for first-quarter 2022. "Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds.
-
Johnson & Johnson Announces Dividend Increase of 6.6%
4/19/2022
Johnson & Johnson announced that its Board of Directors has declared a 6.6% increase in the quarterly dividend, from $1.06 per share to $1.13 per share.
-
Following first-quarter results, Johnson & Johnson is projecting almost $1 billion less in revenue for the year than the initial guidance it gave in January.
-
Pfizer, J&J and GSK indicate plans to file for regulatory approval by the end of this year for vaccines against RSV, which would see vaccines against the disease becoming available in 2023.
-
The FDA has sprung into action, cracking down on the illegal sales of Adderall, as well as on CBD companies making claims their products are effective treatments or cures for COVID-19.
-
Janssen Pharmaceutical, under parent organization Johnson & Johnson, secured an arbitrary win this week that results in royalty decisions stemming from licensing and marketing of daratumumab.
-
COVID-19 has killed more than six million people worldwide and almost one million in the U.S. And the pandemic isn’t over yet. Read on for that and more updates about COVID-19.
-
Johnson & Johnson to Participate in the BofA Securities 2022 Healthcare Conference
4/7/2022
Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities 2022 Healthcare Conference at the Encore Hotel in Las Vegas, Nevada on Wednesday, May 11th.